{"entity":{"id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of VRN110755 in non-small-cell lung cancer and small-cell lung cancer, run by Voronoi, Inc, now recruiting.","summary":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07699328 by Voronoi, Inc, with 315 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-01-01. Interventions recorded: VRN110755. Conditions listed: EGFR-Mutant Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07699328","url":"https://clinicaltrials.gov/study/NCT07699328"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vrn110755"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07699328","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Voronoi, Inc","enrolled":315,"outcomes":[]},"route":"/trials/nct07699328/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/"}]}}